Company: NIVFW
Filing Date: 2025-08-21
Form Type: DRS
Source: 0001213900-25-079301
Chunk: 128

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-21
Form: DRS
Chunk 128
---
   |     |      |    (18,962 | ) |
| Cash and cash equivalents, beginning of year                        |     |                    |     54,104 |   |     |      |     27,556 |   |
| Cash and cash equivalents, end of year                              |     |                    |    457,740 |   |     |      |     54,104 |   |

<div align='center'>73</div>

Operating activities

Net cash used in operating
activities was US$8,264,074 for the year ended December 31, 2024. The difference between NewGenIvf’s net loss of US$474,101
for the year ended December 31, 2024 and the net cash used in operating activities was primarily attributable to (i) an increase
of agent’s receivable of US$1,191,795, (ii) a cash deposit of US$1,000,000 with a digital trading platform and settlement of
charges in relation to the de-spac and business reorganisation.

Net cash used in operating
activities was US$1,766,135 for the year ended December 31, 2023. The difference between NewGenIvf’s net profit of US$108,418 for
the year ended December 31, 2023 and the net cash used in operating activities was primarily attributable to refund of payment from clients
from the contract liabilities and the expenses spent on the legal and professional cost which was capitalized in the book of 2023.

Investing activities

Net cash used in investing
activities in 2024 was US$53,045, primarily representing purchase of plant and equipment.

Net cash used in investing
activities in 2023 was US$69,848, primarily representing purchase of plant and equipment.

Financing activities

Net cash provided by financing
activities in 2024 was US$8,675,790, primarily representing issuance of share capital utilizing equity line of credit, convertible note
issuance and proceeds from issuance of promissory notes all totaling to an amount of $8,583,597.

Net cash provided by financing
activities in 2023 was US$1,881,493, primarily representing amounts advanced to shareholder and repayment of prior loans from related
parties.

Contractual Obligations

The following table sets forth
NewGenIvf’s main contractual obligations and commitments as of December 31, 2024 and December 31, 202